Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.39 - $7.38
Previous CloseN/A
Volume1.06M
Average Volume (3M)424.36K
Market Cap
$79.14M
Enterprise Value-$6.29M
Total Cash (Recent Filing)$74.94M
Total Debt (Recent Filing)$176.00K
Price to Earnings (P/E)―
Beta3.27
Next Earnings
May 14, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding30,674,854
10 Day Avg. Volume409,143
30 Day Avg. Volume424,362
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)64.23
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$32.50Price Target Upside1189.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Sagimet Biosciences, Inc. Class A News
See All SGMT News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe FASCINATE-3 Phase 3 program for denifanstat in F2/F3 MASH patients has started, indicating progress in clinical trials.
Market OpportunitySGMT is considered an attractive play on the broader NASH space, trading at a relative discount to competitors and highly levered to broader NASH market sentiment.
PartnershipsSGMT's partner in China, Ascletis, continues to expect topline results from a Phase 3 trial of denifanstat in acne, where positive data could build further confidence around deni’s safety profile.
Bears Say
Financial PerformanceSGMT reported a 4Q24 net loss of $16.2M, which could be a concern for financial stability.
Research And Development ExpensesSGMT's 4Q24 research and development expenses increased by 12% quarter over quarter, which may impact profitability.
---
Ownership Overview
10.58% Insiders
6.79% Mutual Funds
30.65% Other Institutional Investors
48.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.39 and its highest was $7.38 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $79.14M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is May 14, 2025 which is in 40 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Mar 12, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.621 by $0.121.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.68.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,674,854 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.621. Following the earnings report the stock price went up 3.235%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
---
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (1189.68% Upside)
$32.50 (1189.68% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 428.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.90%
12-Months-Change
Fundamentals
Return on Equity
-36.92%
Trailing 12-Months
Asset Growth
65.70%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences, Inc. Class A (SGMT) is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics targeting key metabolic pathways to treat diseases with unmet medical needs. The company focuses primarily on the development of innovative drugs for the treatment of liver diseases, cancer, and other metabolic disorders, leveraging its expertise in fatty acid synthase (FASN) inhibition.
---
SGMT Stock 12 Month Forecast
Average Price Target
$32.50
▲(1189.68% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
89bio
―
Repare Therapeutics
―
Best Analysts Covering SGMT
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-24.42%
reiterated a buy rating 24 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -24.42% per trade.
---